A Boston-based biotech company is turning heads on Wednesday after the company announced that the first patient was dosed in its Phase 1/2a monotherapy clinical trial of ATRN-119,...

To read the full story on AllPennyStocks.com, click here.

Aprea Therapeutics (NASDAQ:APRE)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Aprea Therapeutics Charts.
Aprea Therapeutics (NASDAQ:APRE)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Aprea Therapeutics Charts.